Free Trial
NASDAQ:KRRO

Korro Bio Q1 2025 Earnings Report

Korro Bio logo
$12.35 +0.47 (+3.96%)
Closing price 06/5/2025 04:00 PM Eastern
Extended Trading
$12.38 +0.03 (+0.20%)
As of 06/5/2025 07:17 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Korro Bio EPS Results

Actual EPS
-$2.49
Consensus EPS
-$2.60
Beat/Miss
Beat by +$0.11
One Year Ago EPS
N/A

Korro Bio Revenue Results

Actual Revenue
$2.55 million
Expected Revenue
$0.13 million
Beat/Miss
Beat by +$2.42 million
YoY Revenue Growth
N/A

Korro Bio Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Wednesday, May 7, 2025
Conference Call Time
4:00PM ET

Upcoming Earnings

Korro Bio's Q2 2025 earnings is scheduled for Tuesday, August 12, 2025, with a conference call scheduled on Wednesday, August 6, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Korro Bio Earnings Headlines

Elon just did WHAT!?
As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they gotten away with it, the Fed and U.S. banks could have seized control of our financial lives forever. But Trump stopped them cold on January 23rd, 2025, when he outlawed CBDCs… Paving the way for Elon Musk's secret master plan.
Korro Bio to Cut 20% of Workforce
Korro Bio to Cut 20% of Workforce
See More Korro Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Korro Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Korro Bio and other key companies, straight to your email.

About Korro Bio

Korro Bio (NASDAQ:KRRO), a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

View Korro Bio Profile

More Earnings Resources from MarketBeat